AML1 (fosfo Ser435) Antilichaam

CBF binds to the core site, 5'-PYGPYGGT-3', of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL-3 and GM-CSF promoters. The alpha subunit binds DNA and appears to have a role in the development of normal hematopoiesis. Isoform AML-1L interferes with the transactivation activity of RUNX1. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the mouse BLK promoter. Inhibits MYST4-dependent transcriptional activation.

861

Q01196

NP_001001890.1

Human, Mouse, Rat

AML1 (phospho Ser435) antibody was raised against a peptide sequence around phosphorylation site of Serine 435 (S-N-S (p) -P-T) derived from Human AML1.

Unconjugated

Primary Antibodies

Phospho-Specific

Antibodies were purified by affinity-chromatography using epitope-specific peptide.

1 mg/mL

Antibody supplied in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Phospho-Specific

Blue Ice

Store antibody at -20˚ C for up to one year.

53 kDa

IgG

The antibody detects endogenous levels of AML1 only when phosphorylated at serine 435.

Western Blot: 1:500~1:1000

RUNX1

Runt-related transcription factor 1

Homo sapiens

Miyoshi H., Proc. Natl. Acad. Sci. U.S.A. 88:10431-10434 (1991) .

Sacchi N., Genes Chromosomes Cancer 11:226-236 (1994) .

Nucifora G., Blood 81:2728-2734 (1993) .

Acute myeloid leukemia 1 protein, CBFA2, CBFA2, alpha 2 subunit, RUNX1

WB

223459612

Liquid